Degarelix monotherapy versus luteinizing hormone-releasing hormone (LHRH) agonists plus antiandrogen flare protection in the treatment of men with advanced prostate cancer.
Bertrand Tombal
Consultant or Advisory Role - Ferring
Honoraria - Ferring
Other Remuneration - Ferring
Jan-Erik Damber
Consultant or Advisory Role - Ferring
Anders Malmberg
Employment or Leadership Position - Ferring
Bo-Eric Persson
Employment or Leadership Position - Ferring
Laurence Klotz
Honoraria - Ferring
Research Funding - Ferring
Peter Iversen
Consultant or Advisory Role - Ferring
Honoraria - Ferring
Other Remuneration - Ferring